TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03645954

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Procedure: Femoral Nerve Block~The femoral nerve block will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 50 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral nerve block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral nerve block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Triangle & Adductor Canal Blocks
Description: Procedure: Femoral Triangle \& Adductor Canal Blocks~These two blocks will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 100 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral triangle block and adductor canal block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral triangle block and adductor canal block (10 mL for each block).
Study: NCT01607112

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix/Influsplit SSW 2012-2013
Description: 1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix/Influsplit SSW 2012-2013
Description: 1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
Study: NCT02370082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Localization of breast lesion
Description: localization of breast lesion for removal
Study: NCT04067375

Intervention type: OTHER
Intervention: Clinical data collection.
Description: The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.

Intervention type: OTHER
Intervention: Clinical data collection.
Description: The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.

Intervention type: OTHER
Intervention: Clinical data collection.
Description: The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.
Study: NCT01710332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection
Description: GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).~GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection
Description: GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).~GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total).
Study: NCT01047423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40mg encapsulated once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated oral once daily for 12 weeks
Study: NCT03861117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assisted strategy
Description: Daily spontaneous breathing trial (SBT) with 7 cmH2O pressure support and 5 cmH2O positive end-expiratory pressure are performed to assess weanability. In case of success, a SBT with T-piece is performed to determine if the patients is at high risk of extubation failure. In this case and/or in the presence of risk factors, systematic non-invasive ventilation is applied after extubation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non assisted strategy
Description: Daily spontaneous breathing trials (SBT) with T-piece are performed to assess weanability. In the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
Study: NCT01095107

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low fat intake
Description: low fat intake : Intake 35-50 grams of fat per day between meals and snacks

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Increased fat intake
Description: increased fat intake : Intake \> 50 grams of fat per day between meals and snacks
Study: NCT03253926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: Lorcaserin 10mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Smoked marijuana cigarette

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Marijuana
Description: Smoked marijuana cigarette
Study: NCT01813370

Intervention type: OTHER
Intervention: No intervention
Description: No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
Study: NCT00709696

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
Study: NCT01747525

Intervention type: DEVICE
Intervention: NIRS/IVUS of coronary artery
Description: Evaluation of coronary plaque by NIRS/IVUS.
Study: NCT04567290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chewed ticagrelor
Description: Chewed ticagrelor (Brilinta) 90 mg tablets, 2 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Swallowed ticagrelor
Description: Swallowed ticagrelor (Brilinta) 90 mg tablets, 2 tablets
Study: NCT00760903

Intervention type: OTHER
Intervention: Conventional MRI of the brain

Intervention type: OTHER
Intervention: Conventional MRI of the brain

Intervention type: OTHER
Intervention: Conventional MRI of the brain

Intervention type: OTHER
Intervention: Conventional MRI of the brain

Intervention type: OTHER
Intervention: Conventional MRI of the brain

Intervention type: OTHER
Intervention: MR spectroscopy (MRS)

Intervention type: OTHER
Intervention: MR spectroscopy (MRS)

Intervention type: OTHER
Intervention: MR spectroscopy (MRS)

Intervention type: OTHER
Intervention: MR spectroscopy (MRS)

Intervention type: OTHER
Intervention: MR spectroscopy (MRS)

Intervention type: OTHER
Intervention: MR Diffusion Tensor Imaging (DTI)

Intervention type: OTHER
Intervention: MR Diffusion Tensor Imaging (DTI)

Intervention type: OTHER
Intervention: MR Diffusion Tensor Imaging (DTI)

Intervention type: OTHER
Intervention: MR Diffusion Tensor Imaging (DTI)

Intervention type: OTHER
Intervention: MR Diffusion Tensor Imaging (DTI)
Study: NCT01060540

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genetic testing for type 2 diabetes
Description: TCF7L2, PPARG, or KCNJ11

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional risk counseling
Description: Risk based on lifetime risk, fasting plasma glucose results, and family history.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional risk counseling
Description: Risk based on lifetime risk, fasting plasma glucose results, and family history.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eye disease counseling
Description: addresses risk for age-related macular degeneration, glaucoma, cataracts
Study: NCT02157922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alginate oligosaccharide
Description: Inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: alginate oligosaccharide
Description: Inhalation
Study: NCT00759915

Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate extended-release capsules
Description: 2 x 10 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: morphine sulfate extended-release capsules
Description: 2 x 10 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate extended-release) capsules
Description: 1 x 20 mg, single-dose capsule

Intervention type: DRUG
Group type: OTHER
Intervention: KADIAN (morphine sulfate extended-release) capsules
Description: 1 x 20 mg, single-dose capsule
Study: NCT01650246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad
Description: Tablets, 400 mg QD
Study: NCT02134977

Intervention type: DRUG
Intervention: Leuprorelin Acetate
Description: Leuprorelin Acetate SR 11.25 mg Injection Kit
Study: NCT01730781

Intervention type: RADIATION
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.

Intervention type: RADIATION
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.

Intervention type: RADIATION
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.

Intervention type: RADIATION
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.

Intervention type: RADIATION
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.

Intervention type: RADIATION
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.

Intervention type: RADIATION
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
Study: NCT04451538

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional intervention group
Description: Supplemental nutritional support is provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase). For non-diabetic patients, ENSURE is provided (Abbott; 112.6 g (12 spoons, 500 kcal)/day, twice a day); for diabetic patients, GLUCERNA SR is provided (Abbott; 104 g \[12 spoons, 440 kcal\]/day, twice a day).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Supplemental nutritional support is not provided in addition to normal diet during the perioperative period (five days from pre- to postoperative phase).
Study: NCT01459419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-CD3 monoclonal antibody
Description: Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride placebo
Description: Sodium chloride will be administered orally every day for 30 days. Up to 9 subjects will be treated at each dosage level. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
Study: NCT03821441

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV(Candy)
Description: A single dose of 1 pill orally of bOPV to subjects aged 48 months who recieved bOPV (candy) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available ,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV(Liquid)
Description: A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who recieved bOPV (liquid) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bOPV(Liquid)
Description: A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who received tOPV (liquid) produced by Beijing Tiantan Biological Products Co., Ltd. in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV.
Study: NCT02669511

Intervention type: DRUG
Group type: OTHER
Intervention: PQR309
Description: Oral PQR309, 80mg or 60mg daily or intermittent dosing
Study: NCT00252733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: candesartan cilexetil
Description: 32 mg once daily oral tablet given over 60 months
Study: NCT02872831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22G SharkCore™ needle
Description: The 2 dedicated passes from the SharkCore™ needle will be placed in a jar with formaldehyde-based fixative and sent for routine histopathology evaluation. The cassette will be processed, embedded in paraffin, and then prepared in hematoxylin and eosin to be evaluated by one pathologist, who was blinded to the randomization sequence, for the presence of a histologic tissue. If adequate histologic tissue is present, the specimen will be graded as optimal or suboptimal.
Study: NCT02110069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine dose dependent upon weight. Weekly for 2 months (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Continuous dosing to maintain trough level of 10-15ng/ml.
Study: NCT02872831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22G BNX EUS-FNA Needle
Description: Aspirates will be placed onto glass slides and preserved with Diff-Quik stain (American Scientific Products, McGraw Park, Illinois, USA). In addition, a smear will also be placed in alcohol for Papanicolaou staining. Any additional material was sprayed into Hanks's solution and sent for cell block processing. The cytology technician or cytopathologist on site will verify adequacy of specimens. At least two passes will be obtained from the lesion unless the technician established the presence of malignant appearing cells.
Study: NCT00081770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: 1.5 ug/kg/week subcutaneously (SC) for 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: 1.0 ug/kg/week SC for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REBETOL (ribavirin; SCH 18908)
Description: weight based dose 800-1400 mg/day orally (PO) for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REBETOL (ribavirin; SCH 18908)
Description: weight based dose 800-1400 mg/day orally (PO) for 48 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEGASYS (peginterferon alfa-2a)
Description: 180 ug/week SC administered for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COPEGUS (ribavirin)
Description: 1000-1200 mg/day PO for 48 weeks
Study: NCT01350336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alair System
Description: Treatment of airways with the Alair System
Study: NCT02080312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnevist (gadopentetate dimeglumine)
Study: NCT01491672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Study drug was supplied as 5 mg tablets in blister packs.
Study: NCT03435497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game Changers
Description: Game Changers is an intervention that aims to empower and mobilize PLHA to be agents for HIV prevention and behavioral change in their social networks.
Study: NCT02835326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Dietary Weight Loss
Description: The EX+DWL intervention consists of group and individual exercise sessions, as well as, nutritional and dietary counseling. Bimonthly phone calls are made in the final year of the study to aid in maintenance of the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walk with Ease
Description: The WWE 6 week program consists of health education lectures on arthritis self-management, a walking exercise portion, and at- home strength exercises. Participants will complete two consecutive WWE programs. Monthly and bimonthly phone calls are made to participants in months 4-12 and 12-24, respectively, to aid in maintenance of the program.
Study: NCT02782403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT05125666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Task Training (Motor + Cognitive)
Description: Each child in this group will perform one-hour session consist of two tasks (cognitive and balance task) in addition to the traditional physical therapy program three times weekly for 8 successive weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Regular Exercise
Description: Each child in this group will receive the selected physical therapy program which include mobility exercises, strengthening exercises, balance exercises, gait training exercises, and exercises to improve physical conditioning for one-hour session three times weekly for 8 successive weeks.
Study: NCT01717690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG antiseptic body cleanser
Description: The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
Study: NCT04662762

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing intervention programme
Description: educational information
Study: NCT02952287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4D PC MRI acquisition
Description: Flow-sensitive 4D-MRI acquisitions will be synchronized to the heart rate and breathing using prospective ECG-gating and adaptive diaphragm navigator gating41. The MRI sequence will consist of a segmented k-space spoiled gradient echo sequence with interleaved 3D velocity encoding. Data will be acquired in a sagittal oblique 3D data volume individually adapted to include the heart and the thoracic and upper abdominal vessels of interest like ascending, transverse and descending aorta, main and branch pulmonary arteries, pulmonary veins, superior and inferior vena cava, celiac and superior mesenteric vessels. Velocity encoding (VENC) will be set at 150-500 cm/sec to encompass flow in various vessels.
Study: NCT03217643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
Study: NCT03815032

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drift assessment of OptoWire Deux FFR wire (1)
Description: Simultaneous data of two different OptoWire DeuxTM guidewires (group 1) to assess a single coronary stenosis and detect any difference if any.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drift assessment of OptoWire Deux FFR wire (2)
Description: Simultaneous data of one Optowire Deux TM guide wires and one VERRATA-TM FFR wire (group 2) to assess a single coronary stenosis and detect any difference if any.
Study: NCT00515320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Once daily oral dispersible tablet 2mg 9mg or 18mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dispersible tablet placebo
Study: NCT02042612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedation with sevoflurane during 48-hr in ICU
Study: NCT04281004

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amniotic Fluid (AFED)
Description: One drop (0.25 mL) of Amniotic Fluid Eye Drops (AFED) in each eye four times daily for seven days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: One drop (0.25 mL) of Saline Solution in each eye four times daily for seven days
Study: NCT01896154

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NPS
Description: Comparison of multiple dietary non-digestible polysaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NPS
Description: Comparison of multiple dietary non-digestible polysaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NPS
Description: Comparison of multiple dietary non-digestible polysaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NPS
Description: Comparison of multiple dietary non-digestible polysaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NPS
Description: Comparison of multiple dietary non-digestible polysaccharides

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NPS
Description: Comparison of multiple dietary non-digestible polysaccharides
Study: NCT00701779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
Study: NCT03628898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00025
Description: Noninvasive pulse oximeter sensor
Study: NCT00589082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaunoXome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicine